| Literature DB >> 33893922 |
George David Batty1, Ian J Deary2, Catharine R Gale2,3.
Abstract
Poorer performance on standard tests of pre-morbid cognitive function is related to an elevated risk of death from lower respiratory tract infections but the link with coronavirus (COVID‑19) mortality is untested. Participants in UK Biobank, aged 40 to 69 years at study induction (2006-10), were administered a reaction time test, an indicator of information processing speed, and also had their verbal-numeric reasoning assessed. Between April 1st and September 23rd 2020 there were 388 registry-confirmed deaths (138 women) ascribed to COVID-19 in 494,932 individuals (269,602 women) with a reaction time test result, and 125 such deaths (38 women) in the subgroup of 180,198 people (97,794 women) with data on verbal-numeric reasoning. In analyses adjusted for age, sex, and ethnicity, a one standard deviation slower reaction time was related to a higher rate of death from COVID-19 (hazard ratio; 95% confidence interval: 1.18; 1.09, 1.28), as was a one standard deviation disadvantage on the verbal-numeric reasoning test (1.32; 1.09, 1.59). While there was some attenuation in these relationships after adjustment for additional covariates which included socio-economic status and lifestyle factors, the two pre-pandemic indicators of cognitive function continued to be related to COVID-19 mortality.Entities:
Keywords: COVID-19; Cognitive function; Cohort
Year: 2021 PMID: 33893922 PMCID: PMC8065311 DOI: 10.1007/s10654-021-00743-7
Source DB: PubMed Journal: Eur J Epidemiol ISSN: 0393-2990 Impact factor: 8.082
Cognitive function and covariates at baseline (2006–2010) according to death from COVID-19 (2020)
| COVID-19 mortality | Hazard ratios (95% CI) | |||
|---|---|---|---|---|
| Yes | No | |||
| Age, year, mean (SD) | 62.7 (6.03) | 56.5 (8.09) | < 0.0001 | 3.07 (2.67, 3.53) |
| Female, N (%) | 145 (35.9) | 273,327 (54.4) | < 0.0001 | 0.48 (0.38, 0.59) |
| Non-white ethnicity | 37 (9.27) | 26,997 (5.41) | 0.001 | 3.75 (2.67, 5.27) |
| Vascular or heart disease, N (%) | 216 (54.3) | 149,139 (29.8) | < 0.0001 | 1.79 (1.46, 2.19) |
| Hypertension, N (%) | 313 (79.9) | 282,324 (57.2) | < 0.0001 | 1.70 (1.32, 2.19) |
| Diabetes, N (%) | 63 (15.8) | 26,345 (5.27) | < 0.0001 | 2.31 (1.75, 3.06) |
| Chronic bronchitis or emphysema, N (%) | 18 (4.46) | 8,334 (1.66) | < 0.0001 | 2.37 (1.47, 3.80) |
| Asthma, N (%) | 34 (8.42) | 57,879 (11.5) | 0.050 | 0.80 (0.56. 1.14) |
| Mental health—Psychiatric consultation, N (%) | 56 (14.1) | 57,625 (11.6) | 0.117 | 1.42 (1.07, 1.88) |
| Current smoker, N (%) | 50 (12.6) | 52,580 (10.5) | < 0.0001 | 1.88 (1.37, 2.59) |
| No physical activity, N (%) | 55 (14.0) | 32,804 (6.63) | < 0.0001 | 2.54 (1.90, 3.40) |
| Drinks alcohol daily/almost daily, N (%) | 85 (21.3) | 101,707 (20.3) | 0.641 | 0.88 (0.69, 1.12) |
| Body mass index, kg/m2, mean (SD) | 29.7 (5.83) | 27.4 (4.80) | < 0.0001 | 1.51 (1.39, 1.65) |
| Lung function, L, mean (SD) | 2.53 (0.87) | 2.81 (0.80) | < 0.0001 | 0.69 (0.60, 0.80) |
| C-reactive protein, mg/L, median (IQR) | 1.72 (0.83, 3.51) | 1.26 (0.63, 2.49) | 0.0001 | 1.26 (1.12, 1.41) |
| High-density lipoprotein, mmol/L, median (IQR) | 1.26 (1.09, 1.52) | 1.40 (1.17, 1.67) | 0.0001 | 0.79 (0.69, 0.90) |
| HbA1C, mmol/mol, median (IQR) | 36.7 (33.8, 40.7) | 35.2 (32.8, 37.9) | 0.0001 | 1.25 (1.16, 1.35) |
| No university education, N (%) | 310 (80.7) | 330,988 (67.3) | < 0.0001 | 1.75 (1.35, 2.26) |
| Neighbourhood deprivation score, median (IQR) | −0.887 (−3.04, −2.48) | −2.14 (−3.64, 0.55) | 0.0001 | 1.45 (1.33, 1.59) |
| Personal service, sales occupations etc., N (%) | 54 (27.8) | 66,160 (19.0) | 0.002 | 1.57 (1.15, 2.16) |
| Verbal-numeric reasoning, mean (SD) | 5.32 (2.20) | 6.02 (2.16) | 0.0002 | 1.32 (1.09, 1.59) |
| Reaction time, msec, mean (SD) | 606.1 (136.4) | 559.9 (118.2) | < 0.0001 | 1.18 (1.09, 1.28) |
Hazard ratios are adjusted for age, sex, and ethnicity and expressed per category, or per SD increase for continuous variables (except for reasoning which is expressed per SD decrease [disadvantage]). The maximum analytical sample of 502,655 people was lower in selected analyses owing to missing data
Hazard ratios (95% confidence intervals) for the association of measures of baseline cognitive function (2006–2010) with death from COVID-19 (2020)
| Adjusted for age, sex, and ethnicity | Adjusted for age, sex, ethnicity, and comorbidity | Adjusted for age, sex, ethnicity, and markers of socioeconomic status | Adjusted for age, sex, ethnicity, and lifestyle factors | Adjusted for age, sex, ethnicity, and biological factors | Adjusted for all covariates | |
|---|---|---|---|---|---|---|
| Verbal-numeric reasoning | ||||||
| 1 (most disadvantaged) | 2.04 (1.30, 3.20) | 1.86 (1.18, 2.93) | 2.22 (1.26, 3.94) | 1.52 (0.95, 2.43) | 2.32 (1.30, 4.14) | 2.33 (1.16, 4.69) |
| 2 | 1.35 (0.86, 2.14) | 1.29 (0.81, 2.03) | 1.34 (0.78, 231) | 1.27 (0.80, 2.01) | 1.62 (0.90, 1.89) | 1.39 (0.73, 2.67) |
| 3 | 1.0 (reference) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| P for trend | 0.002 | 0.007 | 0.006 | 0.082 | 0.004 | 0.019 |
| Per SD disadvantage | 1.32 (1.09, 1.59) | 1.25 (1.04, 1.52) | 1.31 (1.02, 1.67) | 1.16 (0.96, 1.41) | 1.29 (1.01, 1.64) | 1.27 (0.94, 1.71) |
| Reaction time | ||||||
| 1 | 1.0 (reference) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 2 | 0.97 (0.73, 1.30) | 0.92 (0.69, 1.24) | 1.01 (0.67, 1.54) | 0.94 (0.70, 1.27) | 0.90 (0.62, 1.30) | 0.84 (0.50, 1.43) |
| 3 (most disadvantaged) | 1.50 (1.15, 1.95) | 1.40 (1.07, 1.83) | 1.66 (1.13, 2.44) | 1.35 (1.03, 1.77) | 1.50 (1.08, 2.09) | 1.75 (1.10, 2.77) |
| P for trend | 0.001 | 0.003 | 0.004 | 0.009 | 0.003 | 0.006 |
| Per SD disadvantage | 1.18 (1.09, 1.28) | 1.16 (1.07, 1.27) | 1.21 (1.07, 1.37) | 1.15 (1.06, 1.25) | 1.19 (1.07, 1.31) | 1.22 (1.04, 1.43) |
Comorbidities: diagnoses of vascular or heart disease, diabetes, chronic bronchitis or emphysema, asthma, hypertension, and mental illness
Socioeconomic status (SES): educational attainment, occupational classification, and area deprivation. Lifestyle factors: body mass index, smoking status, alcohol intake, and physical activity. Biomarkers: Forced expiratory volume in the first second, and blood concentrations of C-reactive protein, glycated haemoglobin, and high-density lipoprotein